Alzheimer's disease test developer Diadem has named Tamas Bartfai, a neuroscientist and Alzheimer's disease researcher, as chair of its medical advisory board.
Bartfai is an international expert in the development of drugs targeting neurological diseases, including Alzheimer’s disease, the firm said.
In the past, he was a professor, chairman of molecular and integrative neurosciences, and director at the Dorris Neuroscience Center at the Scripps Research Institute, and an adjunct professor at Stockholm University, the University of Oxford, and the University of Pennsylvania.
Bartfai has served as a drug development senior executive or consultant to pharmaceutical companies, including AstraZeneca, Roche, Novartis, and Pfizer. He has also been a consultant to biotech venture capitalists and helped launch a number of biotech startups.